In a LinkedIn post, the company said Ramakrishnan will lead its R&D organization. His focus centers around strengthening Insulet’s capabilities in delivering innovation around the world. Ramakrishnan joins as the company continues to advance its automated insulin delivery technology, including the next-generation Omnipod 6 and fully closed-loop insulin delivery.
Acton, Massachusetts-based Insulet said he brings more than 20 years of experience in the healthcare industry. That includes “deep expertise in medical devices and regulated manufacturing,” Insulet said in a LinkedIn post.
He joins Insulet after spending more than six years with Convatec, according to his LinkedIn profile. Most recently, he served as chief science, innovation and quality officer there.
Prior to Convatec, he also spent six years at Eli Lilly. His most recent title there was chief digital officer and VP, digital health. Other stops include stints at Moderna and Elanco.
Another leadership appointment at Insulet
Ramakrishnan becomes the latest new executive team member at Insulet, just over a year since Ashley McEvoy’s appointment as president and CEO.
McEvoy has continued to shape her leadership team over the last year. Personnel moves at the company include the promotion of Eric Benjamin to the role of chief operating officer (COO) and the naming of Manoj Raghunandanan as chief growth officer in August 2025.
Insulet also appointed Flavia Pease to succeed Ana Maria Chadwick as EVP and CFO in September 2025. The company then added Cristal Downing to its newly created position of chief corporate affairs officer in December 2025.
Earlier this year, the company appointed longtime Stryker leader, Mike Panos, as EVP, chief commercial officer (CCO). In April, Insulet added another executive in longtime J&J leader Chuck Medovich, naming him SVP, chief quality, regulatory and compliance officer.
